Filtrer par genre

In Focus by The Hindu

In Focus by The Hindu

The Hindu

A podcast from The Hindu that delves deep into current developments with subject experts, and brings in context, history, perspective and analysis.

1442 - In Focus-Parley | Are lower MRPs on cancer drugs translating into affordable care?
0:00 / 0:00
1x
  • 1442 - In Focus-Parley | Are lower MRPs on cancer drugs translating into affordable care?

    While the National Pharmaceutical Pricing Authority (NPPA) recent trade margin rationalisation has reduced the prices of several anti-cancer medicines, experts say India needs comprehensive cancer care, stronger price regulation, greater transparency and expanded public healthcare provision to protect patients from catastrophic expenditure. Are lower MRPs on cancer drugs translating into affordable care? Here, we discuss. Guests: Dr. Indu Bhushan, bureaucrat, economist and the first CEO of Ayushman Bharat; Mr. K.M. Gopakumar, legal advisor, senior researcher and public health expert. Host: Bindu Shajan Perappadan Producer: Jude Weston Learn more about your ad choices. Visit megaphone.fm/adchoices

    Thu, 05 Nov 2026
  • 1441 - Agarkar to Ojha: how much power do Indian selectors have?

    With Ajit Agarkar departing his role as the chief selector of the Indian men's cricket team, Pragyan Ojha now leads a reconstituted five-member selection committee. With the 2027 ODI World Cup on the horizon, how much power do Indian cricket selectors really have? In this episode of In Focus, we discuss about Agarkar’s legacy, what to expect from Ojha at the helm, and how selectors build and blood a squad. We also discuss how much say the captain and the coach have, how the scouting network covers India’s enormous domestic talent pool, and whether selectors should explain their decisions in public. Host: Reuben Joe Joseph Guest: Amol Karhadkar, Deputy Editor, Sports Producer: Jude Weston Learn more about your ad choices. Visit megaphone.fm/adchoices

    Tue, 03 Nov 2026
  • 1440 - From the Archives | Can India make cancer care more affordable?

    (This episode was aired on October 5.) From November 9, 2026, the National Pharmaceutical Pricing Authority (NPPA) is implementing a 30% cap on trade margins for 137 anti-cancer drugs. We go back to the episode that spoke of the soaring cancer drug prices and how can a pooled procurement and value based pricing improve affordability of cancer care in India. Every year, we record 15.6 lakh new cancer cases, and 9 lakh deaths due to cancer. More than 90% of India’s working population doesn’t have a stable or formal employment. A majority of them are not adequately covered by health insurance. Taken together, this means high out of pocket expenditure for treatment, which imposes a huge economic burden on the patient’s family. A recent survey showed that the overall prevalence of Catastrophic Health Expenditure (CHE) was 80.4% due to outpatient treatment. Clearly, the stratospheric costs of medicines, diagnostics and consultation fees are unsustainable for most Indians. Doesn’t the government have a responsibility here? Why can’t off-patent drugs be made cheaper? Can centralised, pooled procurement, and value-based pricing improve affordability of cancer care in India? Guest: Dr. Indranil, Professor at the School of Government and Public Policy, OP Jindal Global University. Host: G Sampath, Social Affairs Editor, The Hindu Producer and editor: Jude Weston Learn more about your ad choices. Visit megaphone.fm/adchoices

    Mon, 02 Nov 2026
  • 1439 - How Private Equity Is Driving Up Your Hospital Bills

    For most Indians, the bulk of their medical expenses come out of pocket. In such a scenario, rapidly rising healthcare costs are no less dangerous than any deadly disease. One major reason for cost escalation is the entry of private equity into India’s healthcare sector. A new book, titled ‘The Silent Syndicate: How Big Finance is Destroying India’s Healthcare’ documents how global financial capital is gobbling up Indian hospitals, pharma companies, insurance players, and diagnostic labs. And all of this is happening in a regulatory void, with the state seemingly abandoning its responsibility toward the well-being of its own citizens. How did we let this happen? What is the remedy? Is there a way to keep privatised healthcare both affordable and accountable to patients? We speak with public policy expert and the book’s author, Ameer Shahul. Host: G Sampath Producer: Shiksha Jural Learn more about your ad choices. Visit megaphone.fm/adchoices

    Sat, 31 Oct 2026
  • 1438 - Stem cell therapy for autism: Why has the Supreme Court stepped in?

    Earlier this month, the Supreme Court asked the Central government to issue a clear public protocol to curb malpractice in stem cell therapy for autism spectrum disorder. This follows a judgement given in January this year following a petition that raised concerns about the commercial promotion and administration of stem cell “therapy” for autism. The court examined the scientific and regulatory position and held that, given the evidence available at present, stem cell therapy for ASD could not be offered by medical practitioners as a clinical service outside an approved and monitored clinical trial or research setting. The Health Ministry’s current approved list covers 18 adult and 14 paediatric indications. Autism is not on this list. What are the implications of the Supreme Court order, and why was it necessary? Is stem cell therapy something that is being researched for autism abroad and in India and should this continue? Why is the prevalence of autism believed to be increasing and what should we know about it? Guest: Dr. Ennapadam S. Krishnamoorthy, neuropsychiatrist and founder, Buddhi Clinic, Chennai Host: Zubeda Hamid Producer: Jude Francis Weston Learn more about your ad choices. Visit megaphone.fm/adchoices

    Fri, 30 Oct 2026
Afficher plus d'épisodes